These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36831416)

  • 1. Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female
    Zimovjanova M; Bielcikova Z; Miskovicova M; Vocka M; Zimovjanova A; Rybar M; Novotny J; Petruzelka L
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake and efficacy of bilateral risk reducing surgery in unaffected female
    Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG
    J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
    Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    Wang Y; Song Z; Zhang S; Wang X; Li P
    Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
    Chai X; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Tung N; Weitzel JN; Couch FJ; Hulick PJ; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Blum JL; Domchek SM; Chen J; Rebbeck TR
    Breast Cancer Res Treat; 2014 Nov; 148(2):397-406. PubMed ID: 25311111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center.
    Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS
    Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a
    Stuursma A; van der Vegt B; Jansen L; Berger LPV; Mourits MJE; de Bock GH
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in
    Gaba F; Blyuss O; Tan A; Munblit D; Oxley S; Khan K; Legood R; Manchanda R
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline
    Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M
    Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the
    Jung SM; Ryu JM; Park HS; Park JS; Kang E; Lee S; Lee HB; Youn HJ; Yoo TK; Kim J; Lee JE; Han SA; Kim D; Kim SW;
    J Breast Cancer; 2020 Dec; 23(6):647-655. PubMed ID: 33408890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
    Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
    Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
    Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
    Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
    Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.